Entity

Time filter

Source Type

Seoul, South Korea

Kim D.,Seoul National University | Kim S.-H.,ViroMed Co. | Cho S.-H.,Seoul National University | Shin K.,Seoul National University | Kim S.,Seoul National University
Molecular Immunology | Year: 2011

SOCS3 is well known to negatively regulate various cytokine-mediated signaling responses, but its direct role in the expression of specific cytokines has not been clearly elucidated. To understand the role of SOCS3 in the expression of IL-4, one of the key Th2 cytokines, RBL-2H3 cells (a rat mast cell line) were engineered to express SOCS3 constitutively at a high level or at a lower level using shRNA. In RBL-2H3 cells stably expressing SOCS3, the RNA and protein levels of IL-4 were significantly decreased, while it was opposite in RBL-2H3 cells containing shRNA for SOCS3. Overexpression of SOCS3 was found to reduce the level of calcium ionophore-induced phosphorylation of ERK1/2 and c-Jun transcription factor. Consistent with this data, knockdown of SOCS3 increased the level of phosphorylated ERK1 and ERK2. Taken together, SOCS3 appears to play an important role as a negative feedback inhibitor in the expression of IL-4 by inhibiting serine phosphorylation of c-Jun via the ERK signaling pathway. © 2010 Elsevier Ltd. Source


Patent
Viromed Co. | Date: 2012-03-27

The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.


The present invention relates to a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives, cosmetic composition comprising the same. The hardy kiwifruit reduced blood DHT level, promoted the formation of hair root in mouse model experiment, and inhibited the falling out of hair and improved seborrheic skin disease of volunteers such as keratigenous skin, seborrhea etc.


Patent
Viromed Co. | Date: 2012-11-22

The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the present invention shows superior adenovirus producing ability, as compared with an HEK293 cell which is one of conventional adenovirus producing cell lines. Thus, it is possible to produce a time and cost-saving replication incompetent adenovirus. Therefore, the cell line of the present invention effectively produces a replication incompetent adenovirus and provides a safe and effective dose of adenovirus during gene therapy.


The present invention relates to a composition for preventing or treating neurological diseases including an extract of

Discover hidden collaborations